Boardroom Alpha
Start trial
10-Q primary document
HRTX · Quarterly Report (Form 10-Q) · Filed November 4, 2025

Heron Therapeutics Inc — 10-Q exhibit

hrtx-ex10_8.htm
Heron Therapeutics Inc on Boardroom Alpha
EX-10.8

Exhibit 10.8

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN EXCLUDED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTIONS ARE MARKED [***].

 

AMENDMENT NO. 6

TO

CO-PROMOTION AGREEMENT

 

This Amendment No. 6 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of August 15, 2025 (the “Amendment Effective Date”), by and between Heron Therapeutics, Inc., a Delaware corporation (“Heron”) and Crosslink Network, LLC, a Georgia limited liability company (“Co-Promoter”). Heron and Co-Promoter may each be referred to herein as a “Party” and collectively as the “Parties.”

 

WHEREAS, the Parties entered into and are the current parties to that certain Co-Promotion Agreement, with an effective date of January 5, 2024, as amended (collectively, the “Agreement”); and

 

WHEREAS, the Parties now desire to amend the Agreement accordingly, but only in strict accordance with, and as more particularly described in this Amendment.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each Party to the other, the Parties mutually agree as follows:

1.
Exhibit D, Section 3(a)(i)(1)(A). Section 3(a)(i)(1)(A) within Exhibit D of the Agreement is hereby deleted in its entirety and replaced with the following:

[***]

 

2.
Exhibit D, Section 3(b). Section 3(b) within Exhibit D of the Agreement is hereby deleted in its entirety and replaced with the following:

[***]

 

3.
Entire Agreement; Amendment. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement. This Amendment taken together with the Agreement constitutes the full and complete agreement and understanding between the Parties and shall supersede all prior communications, representations, understandings or agreements, if any, whether oral or written, concerning the subject matter contained in this Amendment and the Agreement, as so amended. No provision of the Agreement as so amended may be modified, amended, waived or discharged, in whole or in part, except by a written instrument executed by the Parties. Except as expressly modified by this Amendment, the Agreement and all of its terms and conditions shall continue in full force and effect.

 

 

[Signature Page Follows]

 

 

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

 

HERON THERAPEUTICS, INC.

 

CROSSLINK NETWORK, LLC

 

 

 

/s/ Craig Collard

 

/s/ Richard Haury

Name: Craig Collard

 

Name: Richard Haury

Title: Chief Executive Officer

 

Title: SrVP/General Counsel

 

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer